Castleman's disease and HIV infection in Australia

HIV Medicine

Volumn 5, Issue 3, 2004, Pages 157-162

  Loi, Sherene ^a   Goldstein, D ^b   Clezy, K ^b,c   Milliken, S T ^d   Hoy, J ^e   Chipman, M ^e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

HIV infection; Kaposi's sarcoma; KSH HHV8; Multi centric castleman's disease

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CD20 ANTIBODY; CD4 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FOSCARNET; INTERLEUKIN 6 ANTIBODY; PREDNISOLONE; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG RESPONSE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SEPSIS; T LYMPHOCYTE;

ADULT; ALKYLATING AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FOLLOW-UP STUDIES; GIANT LYMPH NODE HYPERPLASIA; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; VICTORIA;

EID: 2942652568     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00204.x     Document Type: Article

References (24)

1. Castleman B, Iverson L, Menendez VP. Localised mediastinal lymph-node hyperplasia resembing thymoma. Cancer 1956; 9: 822-830.
2. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia: Am J Clin Path 1978; 69: 86-90.
3. Said JW. Human immunodeficiency virus-related lymphoid proliferations. Semin Diagn Pathol 1997; 14: 48-53.
4. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993; 20: 636-647.
5. Soulier J, Grollet L, Oksenhendler E et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-1280.
6. Soulier J, Grollet L, Oksenhendler E et al. Molecular analysis of clonality in Castleman's disease. Blood 1995; 86: 1131-1138.
7. Oksenhendler E, Duarte M, Soulier J et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10: 61-67.
8. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 2002; 35: 880-882.
9. Lanzafame M, Carretta G, Trevenzoli M, Lazzarini L, Vento Ercole Concia S. Successful treatment of Castleman's disease with HAART in two HIV-infected patients. J Infect 2000; 40: 90-91.
10. Gerard L, Galicier L, Maillard A et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr 2002; 30: 478-484.
11. Gerard L, Galicier L, Boulanger E et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003; 17: 81-87.
12. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3: 1202-1216.
13. Aaron L, Lidove O, Viard JP et al. Castleman's disease in patients infected with HIV. Rep Med Interne 2002; 23: 155-163, (in French).
14. Hsu SM, Waldron JA, Xie SS, Barlogie B. Expression of interleukin-6 in Castleman's disease. Hum Pathol 1993; 24: 833-839.
15. Parravicini C, Chandran B, Corbellino M et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000; 156: 743-749.
16. Oksenhendler E, Boulanger E, Du Galicier LMQ et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002; 99: 2331-2336.
17. Bowne WB, Lewis JJ, Filippa DA et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85: 706-717.
18. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92: 670-676.
19. Nishimoto N, Sasai M, Shima Y et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95: 56-61.
20. Corbellino M, Bestetti G, Scalamogna C et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98: 3473-3475.
21. Marcelin AG, Aaron L, Marcos C et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003; 102: 2786-2788.
22. Kumari P, Schechter GP, Saini N, Benator DA. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. Clin Infect Dis 2000; 31: 602-604.
23. Rieu P, Droz D, Gessain A, Grunfeld JP, Hermine O. Retinoic acid for treatment of multicentric Castleman's disease. Lancet 1999; 354: 1262-1263.
24. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003; 73: 48-53.